VERU - Veru rises ~9% on positive data from animal study trial to treat poxvirus
2023-04-11 10:13:50 ET
- Veru ( NASDAQ: VERU ) said a preclinical study showed that its drug, sabizabulin, to treat prototypical poxvirus, vaccinia virus prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells.
- ( VERU ) is up ~9% .
- The preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the smallpox virus infection or other related infections.
- The company expects to submit the full data set for presentation in future scientific meetings and peer-reviewed publications .
For further details see:
Veru rises ~9% on positive data from animal study trial to treat poxvirus